Article summary
The UK Government has announced a £277m investment into life sciences companies as part of the first tranche of winning grants from the Life Sciences Innovative Manufacturing Fund (LSIMF). The successful companies include Ipsen, Pharmaron, Touchlight, and Randox, which will use the money to support the manufacture of medicines for neurological conditions, critical gene therapy and vaccine components, commercial scale manufacture of DNA, and the modernisation of diagnostic tests. The funding also aims to help grow an innovative economy across the UK, supporting more than 500 jobs at companies across the UK.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial